Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Penumbra Inc (PEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,297,130
  • Shares Outstanding, K 34,503
  • Annual Sales, $ 333,760 K
  • Annual Income, $ 4,660 K
  • 36-Month Beta 0.85
  • Price/Sales 13.43
  • Price/Cash Flow 1,249.32
  • Price/Book 12.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.11
  • Number of Estimates 3
  • High Estimate 0.13
  • Low Estimate 0.09
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.25 +16.75%
on 01/16/19
155.77 -0.13%
on 02/15/19
+23.31 (+17.62%)
since 01/15/19
3-Month
110.84 +40.36%
on 12/24/18
155.77 -0.13%
on 02/15/19
+21.31 (+15.87%)
since 11/15/18
52-Week
97.03 +60.34%
on 02/16/18
167.35 -7.04%
on 06/01/18
+57.37 (+58.42%)
since 02/15/18

Most Recent Stories

More News
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

ABT : 75.25 (+1.73%)
AMED : 136.22 (-1.81%)
PEN : 155.57 (+1.32%)
CSII : 33.60 (+1.69%)
NHNKY vs. PEN: Which Stock Is the Better Value Option?

NHNKY vs. PEN: Which Stock Is the Better Value Option?

PEN : 155.57 (+1.32%)
NHNKY : 15.7300 (+4.45%)
Penumbra Reaches Analyst Target Price

In recent trading, shares of Penumbra Inc have crossed above the average analyst 12-month target price of $153.50, changing hands for $154.33/share. When a stock reaches the target an analyst has set,...

PEN : 155.57 (+1.32%)
Here's Why Investors Should Buy CONMED (CNMD) Stock Now

CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.

WMGI : 31.87 (+1.66%)
PEN : 155.57 (+1.32%)
CNMD : 71.94 (+1.27%)
DXCM : 148.49 (+0.45%)
Boston Scientific Benefits From New Buyouts & Product Launch

Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.

ABT : 75.25 (+1.73%)
AMED : 136.22 (-1.81%)
BSX : 40.01 (+0.23%)
PEN : 155.57 (+1.32%)
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.

EW : 177.78 (+0.94%)
ABT : 75.25 (+1.73%)
AMED : 136.22 (-1.81%)
PEN : 155.57 (+1.32%)
Cardinal Health Strong on Pharmaceutical, Competition Rife

Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.

ABC : 86.66 (+0.24%)
MCK : 135.56 (+0.87%)
PEN : 155.57 (+1.32%)
CAH : 55.48 (-0.04%)
Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance

Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.

WMGI : 31.87 (+1.66%)
PEN : 155.57 (+1.32%)
DXCM : 148.49 (+0.45%)
ECL : 163.48 (+1.16%)
BD Gains From Solid Global Base, Headwinds Anticipated

Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.

WMGI : 31.87 (+1.66%)
BDX : 248.34 (+1.57%)
PEN : 155.57 (+1.32%)
DXCM : 148.49 (+0.45%)
HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors

HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.

WMGI : 31.87 (+1.66%)
HQY : 77.10 (+1.74%)
PEN : 155.57 (+1.32%)
DXCM : 148.49 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade PEN with:

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

2nd Resistance Point 156.84
1st Resistance Point 156.20
Last Price 155.57
1st Support Level 154.51
2nd Support Level 153.45

See More

52-Week High 167.35
Last Price 155.57
Fibonacci 61.8% 140.49
Fibonacci 50% 132.19
Fibonacci 38.2% 123.89
52-Week Low 97.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar